Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting ...
Stargardt programs address ABCA4 payload constraints via dual-AAV platforms (VG801, AAVB-039) and explore first ...
The recent progress and future development of gene therapy could help patients with wet age-related macular degeneration maintain vision, according to a speaker at Retina 2026. Allen C. Ho, MD, of ...
Please provide your email address to receive an email when new articles are posted on . At Clinical Trials at the Summit, Abbey addressed concerns about using gene therapy in both eyes. However, in 11 ...
Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease gene therapy. The candidate improved the structure and function of the ...
Researchers from Harvard Medical School and Spark Therapeutics Inc. tested subretinal NRF2 gene therapy in dry AMD models to investigate whether it could relieve oxidative stress and inflammation.
Get a closer look at the biotech ophthalmology landscape to discover exactly how companies are approaching the treatment of eye diseases.
Ocugen had previously fortified its balance sheet in January through a capital raise, issuing 15 million shares at $1.50 each to generate $22.5 million. Furthermore, the leadership team was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results